Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05924815 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval
A Phase 1 study, sponsored by Cytokinetics.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT05924815 is a Phase 1 study that has completed, run by Cytokinetics. The registered enrollment target is 44 participants.
The verdict
NCT05924815, a Phase 1 study, has completed, sponsored by Cytokinetics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
This is a single-center, 2-part (Part A and Part B) study in healthy participants. Part A (Dose Finding) is an open-label, SAD study to identify the dose for Part B. Part B (TQT Study) is a randomized, double-blind (with respect to aficamten and matching placebo), positive- and placebo-controlled, single-dose, 3-way crossover study to evaluate the effect of aficamten administration on QT/QTc interval.
Interventions
- DRUG Moxifloxacin
- DRUG Aficamten
- DRUG Aficamten-matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2023-05-15 |
| Est. Completion | 2023-11-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05924815
The ClinicalTrials.gov registry entry for NCT05924815 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cytokinetics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Moxifloxacin is the first listed.
NCT05924815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05924815 about?
NCT05924815 is a clinical study titled "Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval". This is a single-center, 2-part (Part A and Part B) study in healthy participants. Part A (Dose Finding) is an open-label, SAD study to identify the dose for Part B. Part B (TQT Study) is a randomized, double-blind (with respect to aficamten and matching placebo), positive- and placebo-controlled, s...
What is the current status of trial NCT05924815?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2023-05-15. Estimated completion is 2023-11-14.
What interventions are being tested in trial NCT05924815?
The interventions under investigation include: Moxifloxacin (DRUG), Aficamten (DRUG), Aficamten-matching Placebo (DRUG).
Who is sponsoring clinical trial NCT05924815?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.